Benitec Biopharma Inc.
For the period ended Jun 30, 2025. Filed Sep 22, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 22, 2025
BNTC$9.28-6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveLoss · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at June 30, 2023 | 1,671,485 | $— | $168,921 | $(167,889) | $(830) | $202 |
| Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of offering costs of $2,964 | 875,949 | — | 27,919 | — | — | 27,919 |
| Issuance of common stock and pre-funded warrants sold for cash, net of offering costs of $2,928 | 5,749,152 | 1 | 37,071 | — | — | 37,072 |
| Exercise of pre-funded warrants | 953,307 | — | — | — | — | — |
| Exercise of Series 2 warrants | 98,039 | — | 190 | — | — | 190 |
| Exercise of common warrants | 738,187 | — | 2,848 | — | — | 2,848 |
| Anti-dilution adjustment to warrants | — | — | 619 | (619) | — | — |
| Share-based compensation | — | — | 830 | — | — | 830 |
| Foreign currency translation loss | — | — | — | — | (62) | (62) |
| Net loss | — | — | — | (21,751) | — | (21,751) |
| Balance at June 30, 2024 | 10,086,119 | $1 | $238,398 | $(190,259) | $(892) | $47,248 |
| Issuance of common stock and pre-funded warrants sold for cash, net of offering costs of $2,252 | 2,043,000 | 1 | 28,207 | — | — | 28,208 |
| Exercise of pre-funded warrants | 2,374,583 | — | — | — | — | — |
| Exercise of Series 2 warrants | 1,553,927 | — | 2,999 | — | — | 2,999 |
| Exercise of common warrants, net of offering cost of $67 | 10,192,840 | — | 39,278 | — | — | 39,278 |
| Share-based compensation | — | — | 17,426 | — | — | 17,426 |
| Foreign currency translation gain | — | — | — | — | 53 | 53 |
| Net loss | — | — | — | (37,917) | — | (37,917) |
| Balance at June 30, 2025 | 26,250,469 | $2 | $326,308 | $(228,176) | $(839) | $97,295 |
F-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.